Pharma giant Biocon appoints Shreehas Tambe as CEO & MD
Kedar Upadhye is Chief Financial Officer
Pharma giant Biocon Limited on Friday announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said, “Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise.
Shreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint. Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with a valuation of USD 5.5 billion.
She further said as the first CEO to lead the combined business, Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare. I am confident he will drive disciplined execution and translate our scale into sustained global leadership.
Meanwhile, Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon.
This leadership transition is part of the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies.
Shreehas Tambe, CEO & Managing Director, Biocon, said the company is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology.
"Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs. As we expand our portfolio and global presence, my focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth," Tambe added.
